Review



mk0339 ne inhibitor  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Merck & Co mk0339 ne inhibitor
    Inhibitors. The manufacturers and working concentrations of the inhibitors used in this study are listed.
    Mk0339 Ne Inhibitor, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mk0339 ne inhibitor/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    mk0339 ne inhibitor - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia"

    Article Title: Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia

    Journal: Journal of cellular immunology

    doi: 10.33696/immunology.6.208

    Inhibitors. The manufacturers and working concentrations of the inhibitors used in this study are listed.
    Figure Legend Snippet: Inhibitors. The manufacturers and working concentrations of the inhibitors used in this study are listed.

    Techniques Used: Concentration Assay, Control

    Healthy volunteer and patient derived CD34+ cells were differentiated for 14 days in the presence or absence of inhibitors. The resultant cells were labeled with antibodies to CD14, CD66b, CD11b, and CD15 surface markers and analyzed using flow cytometry. A. Representative experiment histograms are shown. The proportion of CD14 + /CD66b + and CD11b + /CD15 + positive cells in quadrant 2 are indicated. B. Graphical representation of the percentage of CD66b + /CD14 + and CD11b + /CD15 + cellular subsets of the patients' cells after the addition of NE inhibitors. For each individual experiment, the percentage of cells with a mature phenotype after addition of inhibitor was divided by the percentage measured when only the vehicle control was added and this ratio was plotted. Data from 5 different patients, represented in at least two different experiments. Each individual patient has a different symbol. C. Cell cytospins stained with Kwik-Diff (eosin/methylene blue) were imaged using a Nikon digital camera. Cell differentiation was evaluated at 400x magnification by light microscope. Representative experiments showing the effect of MK0339 and brensocatib inhibitors on healthy volunteer and patient cells are shown.
    Figure Legend Snippet: Healthy volunteer and patient derived CD34+ cells were differentiated for 14 days in the presence or absence of inhibitors. The resultant cells were labeled with antibodies to CD14, CD66b, CD11b, and CD15 surface markers and analyzed using flow cytometry. A. Representative experiment histograms are shown. The proportion of CD14 + /CD66b + and CD11b + /CD15 + positive cells in quadrant 2 are indicated. B. Graphical representation of the percentage of CD66b + /CD14 + and CD11b + /CD15 + cellular subsets of the patients' cells after the addition of NE inhibitors. For each individual experiment, the percentage of cells with a mature phenotype after addition of inhibitor was divided by the percentage measured when only the vehicle control was added and this ratio was plotted. Data from 5 different patients, represented in at least two different experiments. Each individual patient has a different symbol. C. Cell cytospins stained with Kwik-Diff (eosin/methylene blue) were imaged using a Nikon digital camera. Cell differentiation was evaluated at 400x magnification by light microscope. Representative experiments showing the effect of MK0339 and brensocatib inhibitors on healthy volunteer and patient cells are shown.

    Techniques Used: Derivative Assay, Labeling, Flow Cytometry, Control, Staining, Cell Differentiation, Light Microscopy

    Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The images captured from the simulations display the binding sites of the inhibitors MK0339, sivelestat, GW311616, and BAY-678 with the wild-type NE. The inhibitor molecules are highlighted in color and indicated by arrows.
    Figure Legend Snippet: Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The images captured from the simulations display the binding sites of the inhibitors MK0339, sivelestat, GW311616, and BAY-678 with the wild-type NE. The inhibitor molecules are highlighted in color and indicated by arrows.

    Techniques Used: Software, Binding Assay

    Molecular docking simulation analysis. Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The stability of each inhibitor-protein complex was assessed using the free energy of binding (S score in kcal/mol), providing an approximation of binding stability.
    Figure Legend Snippet: Molecular docking simulation analysis. Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The stability of each inhibitor-protein complex was assessed using the free energy of binding (S score in kcal/mol), providing an approximation of binding stability.

    Techniques Used: Software, Binding Assay



    Similar Products

    mk0339 ne inhibitor  (Merck & Co)
    90
    Merck & Co mk0339 ne inhibitor
    Inhibitors. The manufacturers and working concentrations of the inhibitors used in this study are listed.
    Mk0339 Ne Inhibitor, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mk0339 ne inhibitor/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    mk0339 ne inhibitor - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibitors. The manufacturers and working concentrations of the inhibitors used in this study are listed.

    Journal: Journal of cellular immunology

    Article Title: Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia

    doi: 10.33696/immunology.6.208

    Figure Lengend Snippet: Inhibitors. The manufacturers and working concentrations of the inhibitors used in this study are listed.

    Article Snippet: MK0339 NE inhibitor was provided by Merck & Co. (Kenilworth, NJ, USA).

    Techniques: Concentration Assay, Control

    Healthy volunteer and patient derived CD34+ cells were differentiated for 14 days in the presence or absence of inhibitors. The resultant cells were labeled with antibodies to CD14, CD66b, CD11b, and CD15 surface markers and analyzed using flow cytometry. A. Representative experiment histograms are shown. The proportion of CD14 + /CD66b + and CD11b + /CD15 + positive cells in quadrant 2 are indicated. B. Graphical representation of the percentage of CD66b + /CD14 + and CD11b + /CD15 + cellular subsets of the patients' cells after the addition of NE inhibitors. For each individual experiment, the percentage of cells with a mature phenotype after addition of inhibitor was divided by the percentage measured when only the vehicle control was added and this ratio was plotted. Data from 5 different patients, represented in at least two different experiments. Each individual patient has a different symbol. C. Cell cytospins stained with Kwik-Diff (eosin/methylene blue) were imaged using a Nikon digital camera. Cell differentiation was evaluated at 400x magnification by light microscope. Representative experiments showing the effect of MK0339 and brensocatib inhibitors on healthy volunteer and patient cells are shown.

    Journal: Journal of cellular immunology

    Article Title: Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia

    doi: 10.33696/immunology.6.208

    Figure Lengend Snippet: Healthy volunteer and patient derived CD34+ cells were differentiated for 14 days in the presence or absence of inhibitors. The resultant cells were labeled with antibodies to CD14, CD66b, CD11b, and CD15 surface markers and analyzed using flow cytometry. A. Representative experiment histograms are shown. The proportion of CD14 + /CD66b + and CD11b + /CD15 + positive cells in quadrant 2 are indicated. B. Graphical representation of the percentage of CD66b + /CD14 + and CD11b + /CD15 + cellular subsets of the patients' cells after the addition of NE inhibitors. For each individual experiment, the percentage of cells with a mature phenotype after addition of inhibitor was divided by the percentage measured when only the vehicle control was added and this ratio was plotted. Data from 5 different patients, represented in at least two different experiments. Each individual patient has a different symbol. C. Cell cytospins stained with Kwik-Diff (eosin/methylene blue) were imaged using a Nikon digital camera. Cell differentiation was evaluated at 400x magnification by light microscope. Representative experiments showing the effect of MK0339 and brensocatib inhibitors on healthy volunteer and patient cells are shown.

    Article Snippet: MK0339 NE inhibitor was provided by Merck & Co. (Kenilworth, NJ, USA).

    Techniques: Derivative Assay, Labeling, Flow Cytometry, Control, Staining, Cell Differentiation, Light Microscopy

    Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The images captured from the simulations display the binding sites of the inhibitors MK0339, sivelestat, GW311616, and BAY-678 with the wild-type NE. The inhibitor molecules are highlighted in color and indicated by arrows.

    Journal: Journal of cellular immunology

    Article Title: Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia

    doi: 10.33696/immunology.6.208

    Figure Lengend Snippet: Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The images captured from the simulations display the binding sites of the inhibitors MK0339, sivelestat, GW311616, and BAY-678 with the wild-type NE. The inhibitor molecules are highlighted in color and indicated by arrows.

    Article Snippet: MK0339 NE inhibitor was provided by Merck & Co. (Kenilworth, NJ, USA).

    Techniques: Software, Binding Assay

    Molecular docking simulation analysis. Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The stability of each inhibitor-protein complex was assessed using the free energy of binding (S score in kcal/mol), providing an approximation of binding stability.

    Journal: Journal of cellular immunology

    Article Title: Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia

    doi: 10.33696/immunology.6.208

    Figure Lengend Snippet: Molecular docking simulation analysis. Molecular docking simulations for NE inhibitors were conducted using the MOE software package. The simulations utilized ELANE G214R, P139L, and wild-type models of neutrophil elastase. The stability of each inhibitor-protein complex was assessed using the free energy of binding (S score in kcal/mol), providing an approximation of binding stability.

    Article Snippet: MK0339 NE inhibitor was provided by Merck & Co. (Kenilworth, NJ, USA).

    Techniques: Software, Binding Assay